Stockscreener 앱 받기
1.62
0.62%
0.01
시장 영업 전:
1.60
-0.02
-1.23%
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc. Revenue Breakdown – FWB:CWY0 - TradingView
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CMND|Clearmind Medicine Inc|Price:1.628|Chg%:+0.018 - TradingKey
CMND|Clearmind Medicine Inc|Price:1.615|Chg%:-0.045 - TradingKey
Clearmind Medicine Inc (CMND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearmind Medicine Inc (CMND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clearmind Medicine (CMND) Stock Forecast & Analyst Ratings - Moomoo
Clearmind Medicine Inc. (CMND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Clearmind files Hong Kong patent for PTSD treatment compounds - Investing.com
Clearmind Medicine Files Hong Kong Patent Application for PTSD-Targeting Compounds - Quiver Quantitative
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market - Yahoo Finance
Clearmind submits addiction treatment proposal to U.S. HHS By Investing.com - Investing.com Nigeria
Clearmind Medicine Expends Global IP Portfolio With Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‐Billion‐Dollar PTSD Therapeutics Market - Moomoo
Clearmind Medicine comments on federal psychedelic guidance By Investing.com - Investing.com South Africa
Clearmind Medicine comments on federal psychedelic guidance - Investing.com UK
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - The Manila Times
Clearmind reports mucoadhesion results for intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Reports Improved Mucoadhesion for Intranasal MEAI Formulation in Ex Vivo Study - Quiver Quantitative
Clearmind's MEAI formulation stayed longer on nasal tissue in testing - Stock Titan
Clearmind Medicine Inc. sees price surge amid market decline - Intellectia AI
Clearmind shares CMND-100 trial insights - grafa.com
Clearmind reports positive early data from alcohol disorder trial - Investing.com UK
Clearmind reports positive early data from alcohol disorder trial By Investing.com - Investing.com Canada
Clearmind's trial shows promising safety and po... - Pluang
Clearmind Medicine Reports Positive Early Experience in Phase I/IIa Trial of Non-Hallucinogenic MEAI for Alcohol Use Disorder - Quiver Quantitative
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Yahoo Finance Singapore
Clearmind Medicine (CMND) Slides 1.93% as Shares Approach Critical $1.93 SupportVOLD Alert - dars.gov.et
Clearmind Medicine (Nasdaq: CMND) details neuroplastogen-based response to U.S. addiction RFI - Stock Titan
Clearmind Medicine Submits Formal Response To HHS RFI Highlighting MEAI-Based Candidate CMND-100 For Alcohol Use Disorder And Binge Behaviors - marketscreener.com
Clearmind submits addiction treatment proposal to U.S. HHS - Investing.com India
Clearmind submits MEAI addiction treatment prop... - Pluang
Clearmind Medicine Submits Response to HHS RFI Highlighting MEAI-Based CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative - The Manila Times
Clearmind Medicine (CMND) reports successful intranasal MEAI feasibility study - Stock Titan
Clearmind reports MEAI intranasal study progress - grafa.com
Clearmind Medicine : Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration for MEAI - marketscreener.com
CMND Stock Slides As Traders Gauge Cash Runway And Volatility - StocksToTrade
Clearmind advances intranasal delivery studies for addiction drug By Investing.com - Investing.com Nigeria
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI - The Manila Times
Clearmind Medicine Reports Successful Formulation Feasibility for Intranasal MEAI Development Program for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Company Profile & Introduction - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Clearmind Medicine receives U.S. patent for binge behavior treatment - Investing.com UK
Clearmind Medicine receives U.S. patent for binge behavior treatment By Investing.com - Investing.com Australia
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength - The Manila Times
Clearmind Medicine secures new U.S. patent for binge behavior regulators, boosting its global IP portfolio. - Pluang
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Price to earnings forward of Clearmind Medicine Inc. – MUN:CWY0 - TradingView
Price to earnings forward of Clearmind Medicine Inc. – NASDAQ:CMND - TradingView
1.97%
0.83%
자본화:
|
볼륨(24시간):